Little Falls, NJ, March 21, 2013 --(PR.com
)-- Sentrx, industry leader in global pharmacovigilance outsourcing, is staffed with pharmaceutical industry veterans known for their exceptional command of drug safety and all of its related issues. This year Sentrx officially announces that one exceptional member of the Sentrx staff, Dr. Barton Cobert, who currently serves as Pharmacovigilance and Regulatory Affairs Consultant, has also been granted the new role of Sentrx blogger extraordinaire.
CEO of Sentrx, Michael O’Gorman states, “Sentrx’s strategic partnership with Dr. Cobert is invaluable to our organization and his vast knowledge and expertise on everything drug safety and regulatory affairs related made the choice to have him represent us on our blog a simple one. We’re truly honored to have him writing for us and look forward to sharing all the work he submits. I have no doubt that his commentary will be of great significance for all those who subscribe to follow him in Bart’s Corner.”
Bart Cobert, MD, FACP, FACG, is a consultant in drug safety (DS) and pharmacovigilance (PV) with 30 years in the pharmaceutical industry at senior levels and is a founding member and working group chair in ICH. He offers expertise in all areas of strategic pharmacovigilance including data management committees and mock Advisory Committee meetings, as well as FDA and EMA/MHRA/AFSSAPS interactions, compliance, training, risk management (REMS/RMPs), crisis management, medical and safety analyses white papers, and organizational change management. He has written four textbooks on drug safety and is also a board certified gastroenterologist. Bart is now blogging for Sentrx in “Bart's Corner” at www.sentrx.com/bart.
Sentrx is a pioneer in pharmacovigilance outsourcing service and is a leading provider of technology-enabled solutions and services for global drug safety. Its mission is to be the best pharmacovigilance outsourcing company in the world. Sentrx helps pharmaceutical, biotechnology, medical device, and consumer health companies document the safety profile of their products during clinical development and post-approval, enabling them to minimize risks and maximize benefits. To learn more about Sentrx, please visit the company's website at http://www.Sentrx.com, or call 973-812-7575.